The state of Texas currently has 24 active clinical trials seeking participants for Head and Neck Cancer research studies. These trials are conducted in various cities, including Houston, Dallas, San Antonio and Austin.
Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies
NCT06052852
Recruiting
A first-in-human study using BDC-3042 as a single agent and in combination with pembrolizumab in patients with advanced malignancies
Gender:
All
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: NEXT Oncology, Austin, Texas +2 locations
Conditions: Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Head and Neck Cancer, Colorectal Cancer, Non-small Cell Lung Cancer
Register for Updates
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
NCT05704985
Recruiting
This study will evaluate safety, pharmacodynamics and biomarkers of subcutaneous (SC) DK210(EGFR) given as monotherapy and in combination with immunotherapy, chemotherapy or radiation.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/09/2024
Locations: Mary Crowley Cancer Research, Dallas, Texas +2 locations
Conditions: Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer, Gynecologic Cancer, Skin Cancer, Kidney Cancer
Register for Updates
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
NCT03504488
Recruiting
The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Mary Crowley Cancer Research, Dallas, Texas +1 locations
Conditions: Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
Register for Updates
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
NCT03881488
Recruiting
This is a Phase 1, open-label, first-in-human study of CTX-471 administered as a monotherapy or in combination with pembrolizumab in patients with metastatic or locally advanced malignancies that have progressed while receiving an approved PD-1 or PD-L1 inhibitor. The study will be conducted in 2 treatment arms (Monotherapy Arm 1 and Combination Arm 2). Each arm will have two parts: Part 1 Dose Escalation and Part 2 Dose Expansion.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Melanoma, Head and Neck Cancer
Register for Updates
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
NCT05259696
Recruiting
This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/22/2023
Locations: NEXT Oncology, San Antonio, Texas
Conditions: Oncology, Melanoma, Ovarian Cancer, NSCLC, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Cancer, CRC, Colon Cancer, Breast Cancer, Gastric Cancer, EGJ, Esophagogastric Junction Cancer, Head and Neck Cancer, Urothelial Cancer, Bladder Cancer
Register for Updates
Multi-Site Trial of Navigation vs Treatment as Usual for Delays in Starting Adjuvant Therapy
NCT05793151
Recruiting
The goal of this clinical trial is to compare the effectiveness of a navigation-based multilevel intervention (ENDURE) with treatment as usual at decreasing delays starting guideline-adherent postoperative radiation therapy among patients with head and neck cancer. The main questions the trial aims to answer are: Does ENDURE decrease delays starting PORT relative to treatment as usual? Does ENDURE decrease racial disparities in delays starting PORT relative to treatment as usual What are the me... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Michael E DeBakey Veterans Affairs Medical Center, Houston, Texas
Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer, Oral Cavity Cancer, Larynx Cancer
Register for Updates
Topical Dermaprazole for Radiation Dermatitis in Breast Cancer and Head and Neck Cancer Patients (TOPAZ)
NCT05269160
Recruiting
Radiotherapy is a mainstay of treatment in head and neck cancer and breast cancer treatment, typically following surgery and/or chemotherapy. Radiation dermatitis, which involves redness, dryness, and/or peeling of the skin, occurs in up to 95% of patients receiving radiation therapy. There is currently no standard therapy for this treatment-related adverse effect. The aim of this study is to investigate the safety and tolerability (Phase I) and preliminary efficacy (Phase II) of prophylactic es... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
11/13/2023
Locations: Baylor College of Medicine Medical Center - McNair Campus, Houston, Texas +2 locations
Conditions: Radiation Dermatitis, Breast Cancer, Head and Neck Cancer
Register for Updates
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Diagnosing Osteoradionecrosis in Patients With Head and Neck Cancer That Is Primary, Has Come Back, or Has Spread to Other Places in the Body
NCT03145077
Recruiting
This trial studies how well dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) works in diagnosing osteoradionecrosis in patients with head and neck cancer that is primary, has come back, or has spread to other places in the body who are undergoing radiation therapy. DCE-MRI may help doctors to predict osteoradionecrosis in patient with head and neck cancer undergoing radiation therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/06/2023
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Head and Neck Cancer
Register for Updates
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
NCT05500508
Recruiting
A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.
Gender:
All
Ages:
12 years and above
Trial Updated:
10/18/2023
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer, DIPG Brain Tumor, Ovary Cancer, Breast Cancer, Papillary Thyroid Cancer, Head and Neck Cancer, Gastric Cancer, Nsclc, Mesotheliomas Pleural, Mesothelioma Peritoneum, Esophageal Cancer, Diffuse Midline Glioma, H3 K27M-Mutant, Endometrial Cancer, Cervical Cancer, Melanoma, Colorectal Cancer, Glioma, Malignant
Register for Updates
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
NCT04075305
Recruiting
The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/25/2023
Locations: Md Anderson Cancer Center, Houston, Texas
Conditions: Oncology, Breast Cancer, Prostate Cancer, Gynecologic Cancer, Brain Tumor, Brain Cancer, Gynecologic Tumor, Prostate Tumor, Prostate Neoplasm, Breast Tumor, Radiation Toxicity, Quality of Life, Rectal Cancer, Rectal Tumor, Rectal Neoplasms, Lung Cancer, Lung Tumor, Lung Neoplasm, Esophageal Cancer, Esophagus Cancer, Esophageal Tumor, Esophageal Neoplasm, Esophagus Tumor, Esophagus Neoplasm, Pancreatic Cancer, Pancreatic Tumor, Pancreatic Neoplasms, Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Tumor, Tumor, Neoplasms, Bladder Cancer, Bladder Neoplasm, Liver Cancer, Liver Neoplasms, Liver Metastases, Oligometastases
Register for Updates
ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy
NCT03769506
Recruiting
A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 vs Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy
Gender:
All
Ages:
18 years and above
Trial Updated:
09/05/2023
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Head and Neck Cancer
Register for Updates
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
NCT04180371
Recruiting
This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2. The main goals of this study are to: Find the recommended dose(s) of BT5528 that can be given safely to participants alone and in combination with nivolumab Learn more about the side effects of BT5528 Learn about how effective BT5528 is for the treatment of ovarian cancer, urothelial/bladder cancer, lung cancer (NSC... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/14/2023
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, Gastric/Upper Gastrointestinal Cancer
Register for Updates